Status:
COMPLETED
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Upper GI Cancer
Cisplatin Adverse Reaction
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Cisplatin is a potent chemotherapeutic agent that has been widely used to treat many solid tumours. acute renal failure, despite conservative fluid and electrolyte management, frequently reported adve...
Detailed Description
This study will look for possible protective effects silymarin on kidney injury in patients receiving cisplatin.
Eligibility Criteria
Inclusion
- age\>18 years
- diagnosed
- measurable upper gastrointestinal adenocarcinoma
- swallow problem
- would like to participate in the study
- Glomerular filtration rate(GFR)\>45ml/min/1.73m2
Exclusion
- end stage renal disease
- requiring dialysis
- post transplantation
- receiving contrast media during last 72 hours
- chronic use of corticosteroids
- chronic use of angiotensin-converting enzyme inhibitor(ACEI )
- untreated hypo-and hyperthyroidism
- ejection fraction\<60%
- active urinary tract infection
- iver disease ( five fold increase of liver enzyme in asymptomatic or 3 fold increase in symptomatic
- use of other nephrotoxic agents such as aminoglycoside, amphotericin
- karnofsky performance status \<70
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01829178
Start Date
August 1 2013
End Date
September 1 2014
Last Update
May 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tehran University of Medical Science
Tehran, Tehran Province, Iran